<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898309</url>
  </required_header>
  <id_info>
    <org_study_id>CIR-HAE-II-III</org_study_id>
    <secondary_id>#210, April 16, 2</secondary_id>
    <nct_id>NCT04898309</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema</brief_title>
  <official_title>A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR-038 in Comparison With Berinert® for Acute Attacks Relief in Patients With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in&#xD;
      comparison with Berinert® in patients with hereditary angioedema&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary angioedema is a rare, potentially life-threatening genetically determined disease&#xD;
      associated with a deficiency or impairment of the functional activity of the C1-esterase&#xD;
      inhibitor (C1-inhibitor). The main clinical manifestation of hereditary angioedema is&#xD;
      recurrent subcutaneous or submucosal swelling of various localization. Most often, the&#xD;
      development of the disease is based on a mutation in the SERPING1 gene. The prevalence of the&#xD;
      disease in the world ranges from 1:10 000 to 1:150 000. GNR-038 is a recombinant C1 inhibitor&#xD;
      (rhC1INH), which is a complete structural and functional analog of the plasma C1 inhibitor.&#xD;
      Phase I study results showed convincing safety and tolerability evidence of GNR-038.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-stage study. In the first stage - 4 groups are presented. At the second stage - 2 study groups 200 HAE attacks to be randomized in 50 patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>At the first stage - the study will be blinded, at the second stage - open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to symptoms relief onset of acute HAE attack within 24 hours after the end of the drug administration.</measure>
    <time_frame>24 hours</time_frame>
    <description>A persistent decrease in the intensity of symptoms by 20 mm from the initial level on the visual analogue scale (VAS) will be regarded as a relief of symptoms of HAE. 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete resolution of the symptoms of an acute HAE attack within 24 hours after the end of the study drug administration.</measure>
    <time_frame>24 hours</time_frame>
    <description>Persistent absence of symptoms - 0 (zero) mm on the visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to minimum manifestation onset of acute HAE attack symptoms after the completion of study drug administration.</measure>
    <time_frame>24 hours</time_frame>
    <description>Persistent reduction in the intensity of symptoms below 20 (twenty) mm on the visual analogue scale(VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of HAE exacerbation episodes that achieved symptom relief after 1 hour and 4 (four) hours after the end of study drug administration.</measure>
    <time_frame>1 hour; 4 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of attacks with HAE current localization relapse or with the occurrence of a new acute attack of a different localization within 24 (twenty-four) hours after the study drug administration.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of attacks that required additional administration of emergency drugs (human C1-esterase inhibitor or icatibant).</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of attacks that did not respond therapeutically to the study drug administration</measure>
    <time_frame>4 hours; 24 hours</time_frame>
    <description>the lack of relief of HAE symptoms within 4 (four) hours after administration of the drug, the occurrence of a relapse of HAE of the current localization or the occurrence of a new acute attack of another localization within 24 (twenty-four) hours after drug administration, the need to use drugs that can weaken the symptoms of HAE (see drugs that are not recommended to treatment), within 24 (twenty-four) hours after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The intensity of acute HAE attack symptoms within 24 (twenty-four) hours after study drug administration.</measure>
    <time_frame>24 hours</time_frame>
    <description>HAE intensity wiil be measured by visual analogue scale (VAS). 0 mm is the absence of symptoms, 100 mm is the maximum possible intensity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-drug antibody formation.</measure>
    <time_frame>7 and 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of anti-drug antibodies neutralizing activity.</measure>
    <time_frame>7 and 14 days</time_frame>
    <description>Laboratory measurement of antidrug antibody with neutralixing activity.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Study stage 1: GNR-038, 50 МЕ/ kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1 esterase inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study stage 1: GNR-038, 100 МЕ/ kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1 esterase inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study stage 1: Berinert®, 20 МЕ/ kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human C1 esterase inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study stage 1: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study stage 2: GNR-038 in selected dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant C1 esterase inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study stage 2: Berinert®, 20 МЕ/ kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human C1 esterase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNR-038, 50 МЕ/ kg</intervention_name>
    <description>A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 1: GNR-038, 50 МЕ/ kg</arm_group_label>
    <other_name>Recombinant C1 esterase inhibitor, 50 МЕ/ kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNR-038, 100 МЕ/ kg</intervention_name>
    <description>A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 1: GNR-038, 100 МЕ/ kg</arm_group_label>
    <other_name>Recombinant C1 esterase inhibitor, 100 МЕ/ kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berinert®, 20 МЕ/ kg</intervention_name>
    <description>A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 1: Berinert®, 20 МЕ/ kg</arm_group_label>
    <other_name>Human C1 esterase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single intravenous infusion of Placebo less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNR-038. The dose will be selected according to results of stage 1 clinical trial.</intervention_name>
    <description>A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 2: GNR-038 in selected dose</arm_group_label>
    <other_name>Recombinant C1 esterase inhibitor.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berinert®, 20 МЕ/ kg</intervention_name>
    <description>A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.</description>
    <arm_group_label>Study stage 2: Berinert®, 20 МЕ/ kg</arm_group_label>
    <other_name>Human C1 esterase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Men and women 18 years and older at the time of signing the Informed Consent Form.&#xD;
&#xD;
          2. Availability of written informed consent signed by the patient prior to the start of&#xD;
             any procedures related to the study.&#xD;
&#xD;
          3. Confirmed diagnosis of HAE:&#xD;
&#xD;
               -  C4 level &lt;50% of the lower limit of the range of normal laboratory values and one&#xD;
                  of the points below:&#xD;
&#xD;
               -  the C1INH level &lt;50% of the lower limit of the range of normal laboratory values,&#xD;
                  OR&#xD;
&#xD;
               -  the level of C1INH within normal values, while the level of functional activity&#xD;
                  of C1INH is below 50% of the lower limit of the range of normal values.&#xD;
&#xD;
          4. Localization of the edema in the abdominal cavity, in the face area (lips, eyelids,&#xD;
             subcutaneous tissue), limbs, trunk or in the area of the external genitals in the&#xD;
             anamnesis.&#xD;
&#xD;
          5. ≥4 HAE attacks requiring treatment or causing significant functional impairment for 2&#xD;
             consecutive months in the 3-month period prior to Screening, properly documented in&#xD;
             the medical records.&#xD;
&#xD;
          6. Patient's consent to adhere to reliable methods of contraception.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Deviation of the C1q level below the normal limit.&#xD;
&#xD;
          2. B-cell lymphoproliferative diseases in the anamnesis or at the time of inclusion in&#xD;
             clinical trial.&#xD;
&#xD;
          3. The presence of anti-C1INH autoantibodies.&#xD;
&#xD;
          4. Allergic reactions to the components of C1INH drugs or other blood components.&#xD;
&#xD;
          5. Glomerular filtration rate ≤59 ml/min/1.73 m2, calculated by the formula CKD-EPI&#xD;
             Creatinine Equation (2009) (see Appendix).&#xD;
&#xD;
          6. The concentration of peripheral blood leukocytes &gt;20*109/L.&#xD;
&#xD;
          7. Drug addiction, solvent abuse, alcoholism in the anamnesis or at the time of&#xD;
             inclusion.&#xD;
&#xD;
          8. Participation in clinical trials of C1-esterase inhibitor drugs, blood transfusion and&#xD;
             its components during the last 90 days prior to screening.&#xD;
&#xD;
          9. Participation in clinical trials of any other investigational drugs within the last 30&#xD;
             (thirty) days prior to screening.&#xD;
&#xD;
         10. Positive laboratory results for HIV and hepatitis B and C.&#xD;
&#xD;
         11. Pregnancy and lactation.&#xD;
&#xD;
         12. Diseases and conditions associated with thrombosis (myocardial infarction, transient&#xD;
             ischemic attacks, deep and superficial vein thrombosis, and pulmonary embolism) less&#xD;
             than 6 months before the start of the screening period, as well as an increased risk&#xD;
             of arterial or venous thrombosis according to the study doctor's opinion.&#xD;
&#xD;
         13. Concomitant diseases and conditions that according to the study doctor's opinion put&#xD;
             the patient's safety at risk when participating in the study, or that will affect the&#xD;
             analysis of safety data if this disease/condition worsens during the study, including:&#xD;
&#xD;
               -  Mental illness;&#xD;
&#xD;
               -  Diseases of the immune and endocrine system that are not controlled by drug&#xD;
                  therapy (including decompensated diabetes mellitus and thyroid diseases);&#xD;
&#xD;
               -  Hematological diseases requiring chemotherapy;&#xD;
&#xD;
               -  Cancer or cancer in the past medical history, with the exception of cured basal&#xD;
                  cell carcinoma;&#xD;
&#xD;
               -  Decompensated liver diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oksana A. Markova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AO GENERIUM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene V. ZUEV, MD</last_name>
    <phone>+79166419698</phone>
    <email>evzuev@generium.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oksana A. Markova, MD</last_name>
    <phone>+7 9854418959</phone>
    <email>oamarkova@generium.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital 52</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical University</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Scientific Medical Center of General Therapy and Pharmacology&quot;</name>
      <address>
        <city>Stavropol'</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=fdafdfaf-8475-4d3e-810a-e18d4fc64236&amp;CIPermGUID=AEE75E93-3F3E-4A76-8EB1-B57F8C5A48C0</url>
    <description>Clinical trial registry, Ministry of Health of Russian Federation</description>
  </link>
  <link>
    <url>https://clinline.ru/reestr-klinicheskih-issledovanij/210-16.04.2021.html</url>
    <description>Clinical trial registry</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary angioedema</keyword>
  <keyword>Swelling</keyword>
  <keyword>GNR-038</keyword>
  <keyword>C1-inhibitor</keyword>
  <keyword>Mutation</keyword>
  <keyword>SERPING1 gene</keyword>
  <keyword>HAE</keyword>
  <keyword>Genetic disease</keyword>
  <keyword>C1-INH deficiency</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Complement Inactivating Agents</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Angioedema</keyword>
  <keyword>Angioedemas, Hereditary</keyword>
  <keyword>Complement C1 Inhibitor Protein</keyword>
  <keyword>Complement C1 Inactivator Proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

